Onset and duration of immunity to equine influenza virus resulting from canarypox-vectored (ALVAC®) vaccination

Abstract

Equine influenza virus remains an important problem in horses despite extensive use of vaccination. Efficacy of equine influenza vaccination depends on the onset and duration of protective immunity, and appropriate strain specificity of the immune response. This study was designed to test the protective immunity resulting from vaccination with the North American commercial ALVAC® equine influenza vaccine (RECOMBITEK® Influenza, Merial, USA)11RECOMBITEK and PROTEQFLU are registered trademarks of Merial in the United States of America and elsewhere; ALVAC is a registered trademark of Connaught Technologies Corporation in the United States of America and elsewhere; SAS is a registered trademark of SAS Institute, Inc. in the United States of America and elsewhere; QIAAMP is a registered trademark of QIAGEN GmbH in the United States of America and elsewhere; MAXEFFICIENCY is a registered trademark of Life Technologies, Inc. in the United States of America; STATXACT is a registered trademark of Cytel, Inc. in the United States of America; STBLA is a trademark of Life Technologies, Inc. against challenge with American lineage influenza viruses. In experiment 1, 12 ponies were vaccinated twice, at a 35 day interval, using the ALVAC®-influenza vaccine expressing the HA genes of influenza A/eq/Newmarket/2/93 and A/eq/Kentucky/94 (H3N8), and 11 ponies served as unvaccinated controls. Six months after the second vaccination, all ponies were challenged with A/eq/Kentucky/91. In experiment 2, 10 ponies received one dose of the ALVAC®-influenza vaccine, 10 ponies served as unvaccinated controls, and all ponies were challenge infected with A/equine/Ohio/03, 14 days after vaccination. Parameters studied included serological responses, and clinical disease and nasal viral shedding following challenge infection. In experiment 1, following the two-dose regimen, vaccinated ponies generated high titered anti-influenza virus IgGa and IgGb antibody responses to vaccination and demonstrated statistically significant clinical and virological protection to challenge infection compared to controls. Infection with A/eq/Kentucky/91 produced unusually severe signs in ponies in the control group, requiring therapy with NSAID's and antibiotics, and leading to the euthanasia of one pony. In experiment 2 following the one-dose regimen, vaccinates generated IgGa responses pre-challenge, and anamnestic IgGa and IgGb responses after challenge. Vaccinates demonstrated statistically significant clinical and virological protection to challenge infection compared to controls. The results of this study clearly demonstrate the early onset, and 6-month duration of protective immunity resulting from ALVAC®-influenza vaccination against challenge with American lineage equine influenza viruses.